All In MedTech

Device Trial Radar · NCT03820947

VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial

Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early & Advanced Stage Superficial Venous Disease

Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 506 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

506

Actual

Start

Feb 5, 2020

Primary completion

Jun 12, 2024

Study completion Nov 10, 2025

Sponsor

Lead sponsor
Medtronic EndovascularPublic (MDT)
Sponsor type
Industry
First posted
Jan 29, 2019

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous Disease

Conditions

  • Venous Reflux

Interventions

  • VenaSeal™ SystemDevice

    The VenaSeal™ System is the non-tumescent, non-thermal, non-sclerosant device that uses a proprietary medical adhesive delivered endovenously to close the vein.

  • Endothermal Ablation (ETA)Device

    ETA includes EVLA that uses laser or RFA that uses radiofrequency heating to close the vein. Heat is applied in both EVLA and RFA therapies to close the vein. Subject can be treated with either EVLA or RFA if randomized to ETA arm per site's standard practice.

  • Surgical StrippingProcedure

    Surgical stripping involves stripping (removal) of the diseased vein via surgical procedures.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Randomized Study VenaSeal™ System Versus Endothermal Ablation (ETA): Primary Endpoint: Peri-procedural Patient Satisfaction as Measured by a Validated, Patient-centered Venous Treatment Satisfaction Questionnaire (VenousTSQe) at 30 Days.Time frame: 30 days
  2. Randomized Study VenaSeal™ System Versus Surgical Stripping: Primary Endpoint: Peri-procedural Patient Satisfaction as Measured by a Validated, Patient-centered Venous Treatment Satisfaction Questionnaire (VenousTSQe) at 30 Days.Time frame: 30 days
  3. Randomized Study VenaSeal™ System Versus Endothermal Ablation (ETA): Primary Endpoint: Patient Satisfaction as Measured by a Validated, Patient-centered Venous Treatment Satisfaction Questionnaire (VenousTSQs) at 30 Days.Time frame: 30 days

4 more outcomes with a free account

Locations

32 sites in 10 countries. Site status is shown where the registry gives one.

  • Yavapai Regional Medical Center

    Prescott Valley, Arizona

  • PIMA Heart and Vascular

    Tucson, Arizona

  • Valley Vascular Surgical Associates

    Fresno, California

29 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.